Immunic Inc. (NASDAQ:IMUX) went down by -18.28% from its latest closing price compared to the recent 1-year high of $28.21. The company’s stock price has collected -24.33% of loss in the last five trading sessions. Press Release reported 18 hours ago that Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
Is It Worth Investing in Immunic Inc. (NASDAQ :IMUX) Right Now?
Plus, the 36-month beta value for IMUX is at 2.19. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for Immunic Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $60.83. IMUX currently public float of 14.93M and currently shorts hold a 6.31% ratio of that float. Today, the average trading volume of IMUX was 257.53K shares.
IMUX’s Market Performance
IMUX stocks went down by -24.33% for the week, with a monthly drop of -11.05% and a quarterly performance of -8.55%, while its annual performance rate touched 88.20%. The volatility ratio for the week stands at 17.37% while the volatility levels for the past 30 days are set at 9.31% for Immunic Inc.. The simple moving average for the period of the last 20 days is -11.41% for IMUX stocks with a simple moving average of 2.52% for the last 200 days.
Analysts’ Opinion of IMUX
Many brokerage firms have already submitted their reports for IMUX stocks, with SVB Leerink repeating the rating for IMUX by listing it as a “Outperform.” The predicted price for IMUX in the upcoming period, according to SVB Leerink is $45 based on the research report published on October 02nd of the previous year 2020.
Piper Sandler, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $71. The rating they have provided for IMUX stocks is “Overweight” according to the report published on August 26th, 2020.
ROTH Capital gave a rating of “Buy” to IMUX, setting the target price at $64 in the report published on August 07th of the previous year.
IMUX Trading at -8.09% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.23% of loss for the given period.
Volatility was left at 9.31%, however, over the last 30 days, the volatility rate increased by 17.37%, as shares sank -5.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.60% lower at present.
During the last 5 trading sessions, IMUX fell by -24.33%, which changed the moving average for the period of 200-days by +103.19% in comparison to the 20-day moving average, which settled at $18.67. In addition, Immunic Inc. saw 8.44% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at IMUX starting from Whaley Glenn, who purchase 1,000 shares at the price of $18.96 back on Aug 10. After this action, Whaley Glenn now owns 1,000 shares of Immunic Inc., valued at $18,960 using the latest closing price.
Vitt Daniel, the Chief Executive Officer of Immunic Inc., sale 1,300 shares at $15.62 during a trade that took place back on Jul 21, which means that Vitt Daniel is holding 362,877 shares at $20,310 based on the most recent closing price.
Stock Fundamentals for IMUX
The total capital return value is set at -103.86, while invested capital returns managed to touch -97.98. Equity return is now at value -46.30, with -42.50 for asset returns.
Based on Immunic Inc. (IMUX), the company’s capital structure generated 0.89 points at debt to equity in total, while total debt to capital is 0.88. Total debt to assets is 0.79, with long-term debt to equity ratio resting at 0.89. Finally, the long-term debt to capital ratio is 0.88.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.56.